Oncology – Lung
RCT | Gefitinib plus chemotherapy vs. Gefitinib alone in untreated EGFR-mutant NSCLC with brain metastases
16 May, 2023 | 14:30h | UTC
Commentary on Twitter
RCT: In patients with untreated EGFR-mutated non-small cell lung cancer with brain metastases, gefitinib + chemo improved survival and PFS vs gefitinib, with manageable adverse events, and may be a viable first-line treatment. #NSCLC https://t.co/Oe6zHYVsPV pic.twitter.com/oUvs12pYS7
— JAMA Network Open (@JAMANetworkOpen) February 9, 2023
Clinical Trial Update | Pembrolizumab plus chemotherapy in squamous non–small-cell lung cancer
16 May, 2023 | 14:25h | UTCCommentaries:
Original Study: Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer – New England Journal of Medicine
Post-pneumonectomy syndrome: a systematic review of the current evidence and treatment options
15 May, 2023 | 12:45h | UTC
ASTRO/ESTRO Guideline | Treatment of oligometastatic non-small cell lung cancer
4 May, 2023 | 13:44h | UTC
Commentary on Twitter
ASTRO & ESTRO partnered to issue the first guideline on local therapy for oligometastatic lung cancer, out today in #PracticalRadOnc https://t.co/ZiM2RWX394 @ESTRO_RT @IyengarPuneeth @Mat_Guc pic.twitter.com/5DV3fRdn1o
— ASTRO (@ASTRO_org) April 25, 2023
Clinical Trial Update | Adjuvant Osimertinib for resected EGFR-mutated stage IB-IIIA non–small-cell lung cancer
4 May, 2023 | 13:33h | UTCOriginal Study: Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer – New England Journal of Medicine
News Release: Trial shows significant disease-free survival for patients diagnosed with non-small cell lung cancer – Yale University
RCT | Endosonography with or without confirmatory mediastinoscopy for resectable lung cancer
26 Apr, 2023 | 13:56h | UTC
Updated ADAURA trial results | Adjuvant Osimertinib improves disease-free survival in resected EGFR-mutated NSCLC
5 Apr, 2023 | 13:21h | UTCNews Release: Trial Shows Significant Disease-free Survival for Patients Diagnosed With Non-small Cell Lung Cancer – Yale School of Medicine
Expanding Organ Usage: UK study finds organs from patients with a primary brain tumor are a viable option
27 Mar, 2023 | 13:27h | UTCSummary: A national cohort study in the UK investigated the risk of cancer transmission from deceased donors with primary brain tumors to organ recipients. The study found no cases of brain tumor transmission among 778 transplants from 282 donors with primary brain tumors, including 262 from donors with high-grade tumors. Organ transplant survival was equivalent to that in matched controls, and some organs from donors with high-grade tumors were less likely to be transplanted.
The results suggest that the risk of cancer transmission in transplants from deceased donors with primary brain tumors is lower than previously thought. Furthermore, the study indicated that donors with brain tumors provided good-quality organs with favorable risk markers and excellent transplant outcomes. Some organs from donors with high-grade tumors were underutilized, indicating a possible aversion by transplant clinicians or patients to use these organs.
These findings imply that it may be possible to safely expand organ usage from donors with primary brain tumors without negatively impacting outcomes, potentially benefiting many patients waiting for a transplant. Although this might lead to a slight rise in transplant numbers in the UK, the findings may hold particular significance for nations with stricter guidelines, such as the United States. The study’s findings can help transplant clinicians discuss the risks and benefits of accepting organ offers from such donors.
RCT | Sotorasib vs. docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation
20 Mar, 2023 | 13:10h | UTCSotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Commentary on Twitter
Docetaxel is the recommended treatment for non-small-cell lung cancer (NSCLC) at disease progression, but it has shown modest clinical benefit.
The CodeBreaK 200 trial compares the KRAS inhibitor sotorasib with docetaxel in patients with advanced NSCLC.https://t.co/Sk7Rk1lAl2
— The Lancet (@TheLancet) March 9, 2023
Practice Guide | Acquiring tissue for advanced lung cancer diagnosis and comprehensive biomarker testing
9 Mar, 2023 | 14:04h | UTC
RCT | Effects of a respiratory distress symptom intervention for lung cancer breathlessness–cough–fatigue symptom cluster
2 Mar, 2023 | 12:51h | UTC
M-A | Predictors of survival to immunotherapy and chemoimmunotherapy in non-small cell lung cancer
14 Feb, 2023 | 10:34h | UTC
RCT | AI improves nodule detection on chest radiographs in a health screening population
10 Feb, 2023 | 13:55h | UTCNews Release: AI Improves Lung Nodule Detection on Chest X-Rays – RSNA News
RCT | Sublobar resection noninferior to lobal resection for peripheral stage IA non–small-cell lung cancer
9 Feb, 2023 | 14:05h | UTCLobar or Sublobar Resection for Peripheral Stage IA Non–Small-Cell Lung Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Less lung tissue removal needed for early-stage cancer, study finds – Weill Cornell Medical College
Related:
Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial – The Lancet (link to abstract – $ for full-text)
M-A | Prevalence of polypharmacy and potentially inappropriate medication use in older lung cancer patients
9 Feb, 2023 | 13:24h | UTC
M-A | Sensitivity and complications of thoracentesis and thoracoscopy for the diagnosis of malignant pleural effusions
27 Jan, 2023 | 12:11h | UTC
Review | Lung cancer screening: new evidence, updated guidance
26 Jan, 2023 | 12:08h | UTCLung cancer screening: New evidence, updated guidance – Journal of Family Practice
Non-oncogene addicted metastatic non-small-cell lung cancer: ESMO Guideline for diagnosis, treatment and follow-up
23 Jan, 2023 | 13:32h | UTC
Post-trial follow-up | Efficacy and safety of first-line lorlatinib vs. crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer
19 Jan, 2023 | 13:49h | UTCEfficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study – The Lancet Respiratory Medicine (link to abstract – $ for full-text)
Original Study: First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer – New England Journal of Medicine
Commentary on Twitter
NEW—Updated, long-term data from the CROWN study show durable benefit of lorlatinib vs crizotinib in pts w/ treatment-naive, ALK-positive #NSCLC
From Prof Benjamin Solomon & colleagues https://t.co/jfOEMRNEgl pic.twitter.com/SBaRCBEGIy
— The Lancet Respiratory Medicine (@LancetRespirMed) December 19, 2022
A deep learning model may predict future lung cancer risk from a single low-dose chest CT
18 Jan, 2023 | 14:00h | UTCNews Release: Artificial intelligence tool developed to predict risk of lung cancer – Massachusetts General Hospital
Commentary: AI tool predicts lung cancer without radiologists or clinical histories – Health Imaging
RCT | High-dose once-daily thoracic radiotherapy in limited-stage small-cell lung cancer
15 Jan, 2023 | 19:51h | UTCHigh-Dose Once-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538 – Journal of Clinical Oncology (link to abstract – $ for full-text)
ASCO Living Guideline | Therapy for stage IV non–small-cell lung cancer without driver alterations
12 Jan, 2023 | 13:12h | UTCEditorial: ASCO Living Guidelines: The Next Frontier
ASCO Living Guideline | Therapy for stage IV non–small-cell lung cancer with driver alterations
12 Jan, 2023 | 13:13h | UTCEditorial: ASCO Living Guidelines: The Next Frontier
RCT | Durvalumab with or without Tremelimumab plus chemotherapy for metastatic non–small-cell lung cancer.
14 Dec, 2022 | 14:47h | UTCCommentary: Adding Tremelimumab and Durvalumab to Chemo Improves PFS, OS in mNSCLC – Cancer Therapy Advisor
Commentary on Twitter
🙌 POSEIDON: 1L tremelimumab + durvalumab + chemotherapy significantly improve progression-free and overall survival in stage IV non small cell #LungCancer 👉 https://t.co/d6causVZ4u #JCO #ImmunoOnc #Immunotherapy #LCSM @MLJohnsonMD2 #NSCLC pic.twitter.com/aIkCwSAwFe
— Journal of Clinical Oncology (@JCO_ASCO) December 3, 2022
Cohort Study | Association of sinoatrial node radiation dose with atrial fibrillation and mortality in patients with lung cancer.
3 Nov, 2022 | 13:39h | UTCAssociation of Sinoatrial Node Radiation Dose With Atrial Fibrillation and Mortality in Patients With Lung Cancer – JAMA Oncology (link to abstract – $ for full-text)
Commentaries:
Incidental sinoatrial node irradiation may increase AF risk in lung cancer – medwire News
Commentary on Twitter
Incidental irradiation to the sinoatrial node may cause new-onset #AtrialFibrillation & decrease overall survival in patients with #LungCancer receiving concurrent #chemoradiotherapy. https://t.co/hPVSnhp11R #RadOnc #LCSM
— JAMA Oncology (@JAMAOnc) September 27, 2022